NSECertificate under SEBI (Depositories and Participants) Regulations, 20189 Oct 2026 · 9 Oct 2026, 03:59 pm

Certificate under SEBI (Depositories and Participants) Regulations, 2018

Jagsonpal Pharmaceuticals Limited · JAGSNPHARM

✦ AI Summary

Jagsonpal Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and substitution of the depository's name as the registered owner.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Jagsonpal Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Attachments (1)

📄

JAGSNPHARM_09102026155924_Certificate74_5_.pdf

pdf

Download →
View document text
Jagsonpal Pharmaceuticals Ltd ( ::.:&.mu • -~ Sakht Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India) Ph.: +91124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com A CSR Initiative lJAGSONPAL! CIN. : L74899DL1978PLC009181 October 09, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Certificate in terms of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 Dear Sir/ Madam, In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we are enclosing herewith a copy of the certificate received from M/s MCS Share Transfer Agent Limited, the Registrar and Share Transfer Agent of the Company, for the quarter ended September 30, 2026. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance officer Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India) Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070 MCS Share Transfer Agent Limited 179-180, Dsidc Shed, 3rd Floor Okhla Industrial Area, Phase –I New Delhi –110020 PhoneNo:011-41406149-51,Fax:-011-41709881 ,Email: admin@rmcsregistrars.com Website:www.mcsregistrars.com, CINNO.U67120WB2011PLC165872 Ref. MCSSTA/JSP/09/2026 October 6, 2026 JAGSONPAL PHARMACEUTICALS LIMITED PLOT NO 412-415 3RD FLOOR NIMAI TOWER PH-IV ,UDYOG VIHAR SEC-18 GURUGRAM, HARYANA-122015 Sub: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 30th September 2026 Dear Sir/Madam, ln accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the Quarter ended 30th September 2026, we hereby certify/ confirm that within 15 days of receipt of the securities received for dematerialization that: (a) the securities comprised in the said Certificate(s) of Security have been listed on the Stock Exchanges where the earlier issued securities are listed ;and (b) the said Certificate(s) after due verification have been mutilated and cancelled and the name of the depository has been substituted in our records as the registered owner. This is for your information and record. Thanking you, Yours faithfully, For MCS Share Transfer Agent Limited Authorised Signatory